PERSPECTA

News from every angle

← Back to headlines

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity - Taiwan News

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity  Taiwan News

19 Mar, 22:30 — 19 Mar, 22:30
PostShare

Sources

Showing 1 of 1 sources
taiwan-newsMostly Factual22d ago

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity - Taiwan News

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity  Taiwan News

Read full article →

Related Stories

Iloilo Reinstates Health Protocols Amid Extreme Heat

just now

Four arrested for selling P102 million in fake anti-cancer medicines in Makati

just now

Vigilance Urged After Death of Two Children in Abandoned Car

just now

Calapan City heat index hits dangerous 44°C

just now